Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double Blind, Placebo-Controlled Study to Explore the Safety, Tolerability, and Activity of SXC-2023 in Adults With Moderate to Severe Trichotillomania (TTM) When Dosed for 6 Weeks

NCT03797521 is registered in ClinicalTrials.gov with Promentis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03797521
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03797521 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double Blind, Placebo-Controlled Study to Explore the Safety, Tolerability, and Activity of SXC-2023 in Adults With Moderate to Severe Trichotillomania (TTM) When Dosed for 6 Weeks
Lead sponsor
Promentis Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 19, 2018
Completion date
December 16, 2019
Enrollment
128 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

trichotillomania